HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC

Recruiting now · Not applicable

Conditions studied: HER2 Positive or Suspicious Positive Tumors

In brief

To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC

Key facts

Study ID

NCT06548529

Run by

Peking University Cancer Hospital & Institute

People needed

30

Starts

2024-06-01

Expected to finish

2028-12-01

Last updated by the study team

2024-08-23

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged # 18 years old; ECOG 0 or 1;
• Is unresectable or metastatic;
• Patients with HER2 positive or suspicious positive tumors;
• was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane;
• Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
• Receives anti-HER2 ADC treatment
• Life expectancy > 3 months

You may not qualify if…

• Significant hepatic or renal dysfunction;
• Is pregnant or ready to pregnant;
• Cannot keep their states for half an hour;
• Refused to join the clinical research;
• Suffering from claustrophobia or other mental disorders;
• Any other situation that researchers considered it unsuitable to participate in the trial.

Where it is running

• uEXPLORER total-body PET/CT scanner (United Imaging, China) — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.